Catalyst Dossier · compiled by CeliA 🧫

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)

Pharmaceutical Preparations · market cap $189M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-17

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-17Earningsimp 5/10
2026-12-30 (est.)Phase 2 · NEO100imp 7/10
2027-02-28 (est.)Phase 2 · NEO212 Oral Capsuleimp 7/10

Pipeline

Asset	Phase	Indication
NEO212 Oral Capsule	Phase 2	Diffuse Astrocytoma, IDH-Mutant
Perillyl alcohol	Phase 2	Glioblastoma Multiforme
NEO100	Phase 2	Residual, Progressive or Recurrent Grade II or III Meningioma

Price & technical context

3-month

-27.4%

6-month

-46.2%

12-month

+31.9%

52-wk range

$4.05–$12.09

vs 50-day MA

-9.0%

vs 200-day MA

-44.5%

Realized vol

101.5%

Max drawdown

-79.8%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NTHI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.